Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Guardian Pharmacy Services, Inc.
GRDN
NYSE·Healthcare·Medical - Distribution·Mkt cap $2.7B
$42.00
▼ -0.31%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$19.30 - $44.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 104.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized focus on lower-acuity long-term care facilities with tailored solutions
- Proprietary data warehouse and Guardian Compass analytics platform for operational optimization
- Integrated clinical expertise combined with technology for medication management and compliance
- Established network of local pharmacies enabling personalized service and rapid response
- Deep regulatory knowledge and compliance infrastructure specific to LTCF requirements
Bear Case
2 risks
- Low volatility (beta 0.1).
- High premium - requires strong execution
Growth
Stable outlook
Aging U.S. population increasing demand for long-term care facility services
Value
High premium - requires strong execution
Momentum
Strong
+10.9% over 3m
Quality
Stable
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GRDN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 10, 2026
MAY 6, 2026
Reported EPS of $0.29 vs $0.24 consensus (+20.8% surprise). Revenue of $336.6M vs $329.9M expected (+2.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+20.8%
Next: Aug 10, 2026
Revenue trend · last 8Q
—
—
+20%
+20%
+15%
+20%
+17%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$300.0M
$314.4M
$338.6M
$329.3M
$344.3M
$377.4M
$397.6M
$336.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
4.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · May 7, 2026
vs Industry
How GRDN stacks vs Medical - Distribution
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related